BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Multiplicom Launches New Genomic and Somatic Mutation Detection Kits


9/24/2012 10:07:52 AM

Niel, September 24th, 2012 – Multiplicom, a molecular diagnostics company specializing in innovative molecular genetics tests based on massively parallel sequencing (MPS) today announces that it is launching new genomic and somatic mutation detection kits based on its proprietary MASTR technology.

The genomic kits enable PCR amplification of all coding regions of genes known to cause Mucovisidosis, Marfan syndrome, Alport syndrome, Polycystic Kidney Disease, Familial Mediterranean Fever and Duchenne Muscular Dystrophy through the identification of single nucleotide polymorphisms, small deletions/insertions and copy number variations. The EGFR MASTR kit is Multiplicom’s first somatic mutation detection product for the analysis of tumour tissue, targeting exons 18 to 21 of the EGFR gene, key to selecting the most effective treatment options.

These newly launched tests complement Multiplicom’s MASTR product line which can be used in combination with all benchtop MPS instruments. Earlier this month, Multiplicom started shipping BRCA MASTR Dx, its first CE/IVD labelled kit, and is in the process of qualifying other kits for EU regulatory approval.

Dr Dirk Pollet, CEO of Multiplicom, said: “The introduction of the new kits establishes Multiplicom as a European leader in the implementation of MPS in routine diagnostic labs. Multiplicom’s products are simple, easy to use, only require standard equipment and are compatible with MPS equipment from Roche, Life Technologies and Illumina.”

For more information please contact:

Multiplicom

Dr Dirk Pollet, CEO

+32 (0) 3 289 14 00

dirk.pollet@multiplicom.com

College Hill Life Sciences (PR agency for Multiplicom)

Stefanie Bacher / Henry Stanley

+44 (0) 207 457 2020

multiplicom@collegehill.com

About Multiplicom

Multiplicom produces molecular diagnostic kits that enable clinical laboratories to perform affordable testing for personalized medicine. The Company was created in 2011 as a spin-off by the University of Antwerp and VIB. Multiplicom develops, manufactures and commercializes leading-edge and easy-to-use genetic test kits based on the latest molecular diagnostic technologies. The successful introduction of its kits in medical genetics labs proves they are the solution to an increasing demand for nucleic acid based testing that is driven by the scientific evidence that links genetic information to health and disease. For further information please visit www.multiplicom.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES